Genenta Science SpA Sponsored ADR GNTA 深 沪
等待开盘 01-29 09:30:00 美东时间
1.35
-0.190
-12.34%
华盛通- 最 高1.50
- 今 开1.40
- 成交量 97.52万股
- 最 低 1.35
- 昨 收 1.54
- 总市值 2469.14万
- 52周最高 10.00
- 市盈率 静 --
- 换手率 5.33%
- 52周最低 1.26
- 委 比 -44.50%
- 总股本 1828.99万
- 历史最高 13.13
- 量 比 0.08
- 振 幅 9.74%
- 历史最低 1.26
- 每 手 1
- 风险率 0.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers ENvue Medical (NASDAQ:FEED) stock moved upwards by 19.0% to $1.25 duri...
01-28 20:05
Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments
Genenta plans a major shift into defense businesses, backing weapons maker ATC, rebranding as Saentra Forge and reshaping its future as shares see sharp moves.
01-28 01:45
Why Biomx Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket
Shares of Biomx Inc (NYSE:PHGE) rose sharply in pre-market trading after a 13D ...
01-27 17:51
Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator
Genenta Science S.p.A. (Nasdaq: GNTA) is renaming itself as Saentra Forge S.p.A. and transitioning to focus on acquiring majority ownership in privately held Italian companies operating in national security sectors under the Golden Power framework. Its first acquisition is ATC, a high-precision manufacturer of tactical rifles and special-forces weapons. The company has also welcomed Praexidia Foundation as a long-term strategic shareholder to sup...
01-27 08:00
Genenta Science Provides Update on CEO Ownership
Genenta Science's CEO and Co-Founder, Pierluigi Paracchi, owns 2,326,129 ADSs and ordinary shares, representing approximately 10% of the company's outstanding share capital. Paracchi has acquired these shares through open-market purchases with no reported sales. The company, focused on gene therapy for solid tumors, is developing Temferon™, a hematopoietic stem cell therapy, with Phase 1 trials completed for GBM and Phase 1/2a initiated for metas...
2025-12-19 07:30
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Genenta Science, a biotechnology company, reported updated results from its TEM-GBM study for newly diagnosed glioblastoma multiforme (GBM) patients with an unmethylated MGMT gene promoter. As of November 21, 2025, 25 patients treated with Temferon showed consistent survival metrics compared to April 2025 data: 44% reached 18-month survival, 29% achieved two-year survival, and median overall survival remained at 17 months. A patient reached three...
2025-11-24 09:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 18.6% to $2.1...
2025-11-21 05:06
Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket
Shares of Teradyne Inc (NASDAQ:TER) rose sharply in today's pre-market trading ...
2025-10-29 17:05
Genenta Science通过定向增发筹集1500万美元
美股周一早盘，临床阶段生物技术研发商Genenta Science（GNTA）股价暴跌43.4%，此前该公司宣布通过定向增发筹集1500万美元，股价交易于...
2025-10-27 22:47
Genenta Science Appoints New Board Member and Confirms CEO
Genenta Science SpA Sponsored ADR ( ($GNTA) ) has shared an update. On April 29...
2025-10-27 18:28
